All News
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
Read Article
JAK Inhibitors in Giant Cell Arteritis
Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.
Difficult-to-Treat Psoriasis
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
Read Article
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Read Article
Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc
Dr. John Cush RheumNow ( View Tweet)
ChatGPT in Rheumatology and Qualitative Research
Dr. Bella Mehta discusses abstract OP0158 presented at Eular 2024 in Vienna, Austria.
https://t.co/2EGLJdK2Pl https://t.co/AaRFqyo6jq
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13
Dr. John Cush RheumNow ( View Tweet)
Finnish study of 331 systemic sclerosis (SSc) pts found that SSc is the major cause of death in diffuse & limited SSc. Among 91 deaths, the 5 & 10 year survival was 88% and 80%. Most common cause death was SSc (n=35)& ILD (13). https://t.co/m30CoAdsMN https://t.co/Ms9LN7eAUK
Dr. John Cush RheumNow ( View Tweet)
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/45OM0PLtjM
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 387 lupus nephritis pts found pulmonary HTN in 15%. An increased risk of PH was seen w/ eGFR <30, and w/ low Hgb, low triglycerides. PH was independently associated with a higher risk (HR ~ 2.0) of all-cause mortality and adverse renal outcomes https://t.co/hdLjOZc9TI https://t.co/60lhdo93lm
Dr. John Cush RheumNow ( View Tweet)
Planetary Health in Rheumatology
Dr. Antoni Chan interviews Dr. Nelly Ziade about her session Planetary Health, presented at Eular 2024 in Vienna, Austria.
https://t.co/gBkwyO1dWQ https://t.co/VvGqwi6tlJ
Dr. John Cush RheumNow ( View Tweet)
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y
Dr. John Cush RheumNow ( View Tweet)
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/rNOARWzEcI https://t.co/xebXgsouta
Dr. John Cush RheumNow ( View Tweet)
Top 10 Drug companies (revenue)
10 Regeneron $12.2b
9 Vertex $8.9b
8 Amgen $26.3b
7 Gilead $27.3b
6 Lilly $28.5b
5 BMS $46.2b
4 Merck $59.3b
3 AbbVie $58.1b
2 J&J $94.9b
1 Pfizer $100.3b https://t.co/GNlGToGcb1 https://t.co/OWyVUBzeO6
Dr. John Cush RheumNow ( View Tweet)
JAMA: 3 prospective cohort studies in USA show that multivitamin use by 390 124 healthy adults did not alter mortality risk (HR, 1.04; 95% CI, 1.02-1.07) https://t.co/VDxrI5Bskw https://t.co/o9wdITR0UT
Dr. John Cush RheumNow ( View Tweet)
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis.
https://t.co/KmAFGwx414 https://t.co/ag5W9j9Kky
Dr. John Cush RheumNow ( View Tweet)
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/JWX5SBEvT5 https://t.co/MrMFmOyQqa
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/hMmrifhiNN https://t.co/LPHc5GyOaA
Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria
https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC
Dr. John Cush RheumNow ( View Tweet)